

Drug resistance interpretation: PR	
PI Major Mutations:	None
PI Accessory Mutations:	None
PR Other Mutations:	K20R <small>100% seen 1,865</small> • R41K <small>99% seen 1,527</small> • I62V <small>99% seen 1,100</small> • L63P <small>100% seen 1,108</small> • G68E <small>99% seen 1,308</small> • H69K <small>99% seen 1,317</small> • A71T <small>99% seen 1,362</small> • I72IM <small>1,867% seen 1,363</small> • V77I <small>99% seen 1,370</small> • I93L <small>100% seen 1,319</small>
Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible
PR comments	
Other	
<ul style="list-style-type: none"> K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations. A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations. 	

No drug resistance mutations were found for PI.

NRTI Mutations:	None
NNRTI Mutations:	None
RT Other Mutations:	V60I ^{100%} _{resistance:2,214} • D121H ^{100%} _{resistance:8,905} • K122E ^{99%} _{resistance:2,801} • I135T ^{99%} _{resistance:2,802} • D177E ^{100%} _{resistance:6,236} • Q207E ^{99%} _{resistance:1,048} • R211K ^{99%} _{resistance:1,887} • V245K ^{100%} _{resistance:2,281} • A272S ^{100%} _{resistance:2} • K277R ^{100%} _{resistance:1} • K281R ^{100%} _{resistance:2} • L282C ^{100%} _{resistance:2} • T286A ^{100%} _{resistance:3} • I293V ^{100%} _{resistance:8}
<hr/>	
Nucleoside Reverse Transcriptase Inhibitors	Non-nucleoside Reverse Transcriptase Inhibitors
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

Mutation scoring: RT HVD8 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.